Our overall objective is to develop approaches for effective vaccination against pulmonary tularemia. Our strategy will involve an innovative combination of vaccine approaches that will exploit TLR/NLR agonists identified in Subproject 2 and anti-oxidant F tularensis (Ft) mutants developed in Subproject 3. During the previous funding period, we made considerable progress (see Program Overview), including the demonstration that significant protection in C57BL/6 mice against the highly virulent type A strain of Ft, SchuS4, can be induced by i.n. inoculation of FcR-targeted inactivated LVS ( Ft). This is the first case to our knowledge in which an inactivated vaccine has provided protection against Ft SchuS4. In addition, anti-oxidant mutants (AAO) of Ft were found to induce partial protection against SchuS4 in the highly sensitive C57BI/6 mouse strain. In this renewal application, we will further optimize conditions for mucosal vaccination, characterize the effects of pulmonary vaccination, and define the cellular and humoral mechanisms responsible for protective immunity against SchuS4. Specifically, we will: 1) Determine the ability of i.n. vaccination with FcR-targeted immunogens in combination with use of anti-oxidant mutants (AAO) of Ft generated in Subproject 3, and /or TLR/NLR agonists identified in Subproject 2, to maximally enhance the immune response to, and levels of protection against, mucosal (i.n.) challenge with Ft SchuS4 at challenge doses up to 20,000 CPU;2) Establish the impact of Ft LVS, AAO Ft LVS and AAO Ft SchuS4, both in live and inactivated forms, on processing and presentation by M0 and DC of non-targeted and FcRtargeted Ft antigen in the presence or absence TLR/NLR agonists;and 3) Define the effector mechanisms responsible for enhanced protection after i.n. vaccination with protective immunogens identified in Aim 1 including testing the postulate that synergy between humoral and cellular immune mechanisms is required for induction of effective protection. The roles of TLR/NLRs and ROS/RNS in both inductive and effector phases will also be examined by using genetically deficient mice and specific agonists/antagonists, in consultation with the PLs of subprojects 2 and 3. The results of subproject 1 will allow the design of new mucosal vaccination platforms for effective biodefense against infection with virulent Ft and will provide novel insight into the pulmonary immune mechanisms that are responsible for protection against respiratory tularemia.

Public Health Relevance

The results of this subproject will allow the design of new mucosal vaccination strategies for effective biodefense against infection with virulent Ft and will provide novel insight into the pulmonary immune mechanisms that are responsible for protection against respiratory tularemia.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01AI056320-10
Application #
8711173
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Albany Medical College
Department
Type
DUNS #
City
Albany
State
NY
Country
United States
Zip Code
12208
Dixon, Ann M; Drake, Lisa; Hughes, Kelly T et al. (2014) Differential transmembrane domain GXXXG motif pairing impacts major histocompatibility complex (MHC) class II structure. J Biol Chem 289:11695-703
Pham, Giang H; Iglesias, Bibiana V; Gosselin, Edmund J (2014) Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells. Vaccine 32:5212-20
Furuya, Yoichi; Wijesundara, Danushka K; Neeman, Teresa et al. (2014) Use and misuse of statistical significance in survival analyses. MBio 5:e00904-14
Ma, Zhuo; Banik, Sukalyani; Rane, Harshita et al. (2014) EmrA1 membrane fusion protein of Francisella tularensis LVS is required for resistance to oxidative stress, intramacrophage survival and virulence in mice. Mol Microbiol 91:976-95
Singh, Anju; Rahman, Tabassum; Malik, Meenakshi et al. (2013) Discordant results obtained with Francisella tularensis during in vitro and in vivo immunological studies are attributable to compromised bacterial structural integrity. PLoS One 8:e58513
Furuya, Yoichi; Kirimanjeswara, Girish S; Roberts, Sean et al. (2013) Increased susceptibility of IgA-deficient mice to pulmonary Francisella tularensis live vaccine strain infection. Infect Immun 81:3434-41
Mahawar, Manish; Rabadi, Seham M; Banik, Sukalyani et al. (2013) Identification of a live attenuated vaccine candidate for tularemia prophylaxis. PLoS One 8:e61539
Metzger, Dennis W; Salmon, Sharon L; Kirimanjeswara, Girish (2013) Differing effects of interleukin-10 on cutaneous and pulmonary Francisella tularensis live vaccine strain infection. Infect Immun 81:2022-7
Iglesias, Bibiana V; Bitsaktsis, Constantine; Pham, Giang et al. (2013) Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen. Immunol Cell Biol 91:139-48
Dotson, Rachel J; Rabadi, Seham M; Westcott, Elizabeth L et al. (2013) Repression of inflammasome by Francisella tularensis during early stages of infection. J Biol Chem 288:23844-57

Showing the most recent 10 out of 38 publications